San Diego-primarily based Viking Therapeutics marked itself as a significant competitor from the weight loss drug marketplace in February following revealing promising facts from the mid-phase demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in M